Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $14.76 USD
Change Today -0.24 / -1.60%
Volume 363.0
INNL On Other Exchanges
As of 3:11 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

innocoll ag-spon adr (INNL) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/12/15 - $16.46
52 Week Low
10/14/14 - $4.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INNOCOLL AG-SPON ADR (INNL)

Related News

No related news articles were found.

innocoll ag-spon adr (INNL) Related Businessweek News

No Related Businessweek News Found

innocoll ag-spon adr (INNL) Details

Innocoll AG, a specialty pharmaceutical company, manufactures and sells collagen-based pharmaceutical products and devices in Europe, the Middle East, Asia, and the United States. The company’s products comprise CollaGUARD, a transparent bioresorbable collagen film for the prevention of post-operative adhesions in various surgical applications, including digestive, colorectal, gynecological, and urological surgeries in open and laparoscopic approaches; Collatamp Gentamicin surgical implant for the treatment or prevention of post-operative infection; Septocoll, a bioresorbable dual-action collagen sponge for the treatment or prevention of post-operative infection; and RegenePro, a bioresorbable collagen sponge for dental applications. Its products also include XaraColl, an implantable and bioresorbable collagen sponge that is in phase III clinical trials for the treatment of post-operative pain relief; and Cogenzia, a topically applied bioresorbable collagen sponge, which is in phase III efficacy trials for the treatment of diabetic foot infections. The company is headquartered in Athlone, Ireland.

83 Employees
Last Reported Date: 04/23/15

innocoll ag-spon adr (INNL) Top Compensated Officers

Chairperson of The Management Board and Chief...
Total Annual Compensation: $32.4K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: $464.6K
Head of Portfolio Operations
Total Annual Compensation: $619.8K
Compensation as of Fiscal Year 2014.

innocoll ag-spon adr (INNL) Key Developments

Innocoll AG Announces Executive Changes, Effective from September 01, 2015

Innocoll AG announced that Jose (Pepe) Carmona, previously the Chief Financial Officer of a division of Alcon, has been appointed Chief Financial Officer effective September 1, 2015. Gordon Dunn, Innocoll's current Chief Financial Officer, will continue with the company as Vice President, Finance Director, Europe. The executive changes were made to add further commercialization experience to the senior management team as the company prepares to transition to a fully-integrated specialty pharmaceutical company. Mr. Carmona has over 19 years of experience applying his extensive management skills toward the financial operations of commercial-stage companies. Most recently he served as Chief Financial Officer of Alcon Europe, Middle East & Africa, a division of Novartis, and prior to that he held numerous financial management positions with increasing responsibility within Novartis. Before joining Novartis in 2003, Mr. Carmona held senior management positions for several divisions of Proctor and Gamble in Latin America.

Innocoll AG Announces Cogenzia Gentamicin Collagen Matrix Receives Qualified Infectious Disease Product Designation for Adjunctive Treatment of Moderate and Severe Diabetic Foot Infection from the FDA

Innocoll AG announced that the Cogenzia gentamicin collagen matrix has received Qualified Infectious Disease Product (QIDP) designation for the adjunctive treatment of moderate and severe diabetic foot infection from the FDA. The QIDP designation was established as part of the Generating Antibiotic Incentives Now (GAIN) Act, passed by the U.S. Congress in July 2012, to increase the incentives for drug manufacturers to produce new antibiotics for serious and hard-to-treat bacterial and fungal infections. Receiving QIDP designation means that Cogenzia is now eligible for additional FDA incentives in the approval and marketing path, including Fast Track designation and Priority Review for development and a five-year extension of market exclusivity. Diabetic foot ulcers are a serious health concern and affect approximately 7% of diabetic patients each year. Up to approximately 58% of these ulcers may become infected. Published data demonstrates that the current standard of care for diabetic foot infections (DFIs) with systemic antibiotics has a 30-50% failure rate. Failure of treatment can lead to significantly increased risk of hospitalization and often to the need for amputation resulting in increased costs to the healthcare system and a much higher risk of mortality for patients. They believe that Cogenzia has the potential to be the first topical antibiotic approved as adjunctive therapy for the treatment of DFIs and that it could significantly improve upon the current cure success rate. Cogenzia acts in conjunction with systemic antibiotics and standard wound care to provide high concentrations of gentamicin directly to the site of DFIs. These concentrations are not normally possible with systemic gentamicin treatment due to the risk of side effects. In the Cogenzia Phase 2 program, data demonstrated a statistically significant improvement in the clinical cure rate when compared to systemic antibiotics and wound care alone. In the Phase 2 study, 100% of Cogenzia-treated subjects experienced a clinical cure compared to 70% for the control group.

Innocoll AG Presents at JMP Securities Life Sciences Conference, Jun-24-2015 12:30 PM

Innocoll AG Presents at JMP Securities Life Sciences Conference, Jun-24-2015 12:30 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States. Speakers: Anthony P. Zook, Chairperson of The Management Board, Chief Executive Officer and Member of Management Board.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INNL:US $14.76 USD -0.24

INNL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $38.09 USD +0.39
Durect Corp $2.49 USD 0.00
Sanofi €96.88 EUR +0.78
View Industry Companies

Industry Analysis


Industry Average

Valuation INNL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 72.7x
Price/Book 9.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 75.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNOCOLL AG-SPON ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at